New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types

About this update from Biovica International Ab Class B

UPPSALA, SE / ACCESS Newswire / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals. The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature. " It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica. Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge. More about the List of abbreviations BC Breast Cancer BL Base Line - prior to treatment BRAF V600 BRAF is a human gene responsible for producing the protein B-Raf, which is involved in signaling direct cell growth. The V600E mutation describes an amino acid substitution at position 600 in BRAF from a valine (V) to a glutamic acid (E) CDK4/6i CDK4/6 inhibitor treatments DFS Disease-Free Survival HER2 Human Epidermal Growth Factor Receptor 2 HR Hormone receptor HR+ Hormone receptor-positive MBC Metastatic Breast Cancer OS Overall Survival Pts Patients TKa Thymidine Kinase activity Contact Anders Rylander, CEO Phone: +46 76 666 16 47 E-mail: [email protected] Anders Morén, CFO Phone: +46 73 125 92 46 E-mail: [email protected] Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com Attachments New DiviTum® TKa data to be presented at ASCO in three cancer types SOURCE: Biovica International View the original press release on ACCESS Newswire

View stock analysis, news, and events for Biovica International Ab Class B